Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
Latest News

Glenmark receives USFDA approval for Milnacipran Hydrochloride tablets

The USFDA has provided its tentative approval to Glenmark Pharmaceuticals for Milnacipran Hydrochloride tablets.

It has said in a BSE filing that “Glenmark Pharmaceuticals Inc, USA, has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Milanacipran Hydrochloride tablets, 12.5 mg, 25 mg, 50 mg and 100 mg.”

Milnacipran Hydrochloride tablets are a generic version of Savella drug, 12.5 mg, 25 mg, 50 mg and 100 mg of Allergan Sales LLC.

Read EquityPandit’s Technical Analysis on Nifty Pharma

Get Daily Prediction & Stocks Tips On Your Mobile